BioSpace News Archive

Xenetic Biosciences, Inc. today announced a research and development collaboration to develop Neutrophil Extracellular Traps targeted, adoptive cell therapies for the treatment of cancer.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent & Trademark Office has issued three new patents to ENDRA including U.S. Patent No. 11379343 (the ‘343 patent), U.S. Patent No. 11392479 (the ‘479 patent) and U.S. Patent No. 11405470 (the ‘470 patent).

Gracell Biotechnologies Inc. today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 15, 2022.

Renovion, Inc., a clinical-stage pharmaceutical company focused on developing treatments for serious chronic inflammatory lung diseases with high unmet needs, announced today that they have received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial to investigate ARINA-1 in the prevention of Bronchiolitis Obliterans Syndrome (BOS) progression in patients that have had a bilateral lung transplant.

OcuTerra Therapeutics, Inc. today announced the first patient was dosed in its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy with minimal vision loss.

Orthofix Medical Inc. today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on August 1, 2022 as inducement material to such employee entering into employment with KalVista.

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report financial results for the second quarter 2022 and provide business updates.

Context Therapeutics Inc. and The Menarini Group announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader, elacestrant.

Incyte (Nasdaq:INCY) today reports 2022 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.